On the way to $100 billion: Eli Lilly reveals huge jump in revenue

Pharmaceutical giant Eli Lilly released financial reports showing a surge in revenue, driven primarily by demand for its weight-loss drugs. The company holds 60% of the US weight-loss market, with quarterly revenues of $14 billion from Mounjaro and Zepbound. Medicare coverage expansion and the launch of a new pill strengthen its position against Novo Nordisk.

Pharmaceutical giant Eli Lilly released its latest quarterly financial reports, indicating a significant surge in revenue. The main growth driver is the high demand for its weight-loss drugs, Mounjaro and Zepbound, administered as weekly injections. The company holds a 60% market share in the United States, compared to just 38% for its main competitor Novo Nordisk, the manufacturer of Ozempic and Wegovy. Quarterly revenues from weight-loss drugs totaled approximately $14 billion, out of total revenues of $23 billion. Two new growth engines are strengthening Eli Lilly's position: the entry of government health insurance Medicare into covering the drugs, which has already brought in about 700,000 new patients, and the launch of the new weight-loss pill Orforglipron, which captured 30% of new patients in the category. The global weight-loss drug market is expected to reach a value of nearly $100 billion by 2030. The article presents the data from an investment-friendly perspective, using terms like 'promising investment opportunity' and 'excellent news' for investors.